The contribution of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway to intrathymic negative selection is a controversial subject with two studies suggesting a key role for TRAIL, while others demonstrated normal negative selection, in TRAIL-and TRAIL receptor-deficient mice. The basis of these discrepancies is unclear and may in part reflect differences in the negative selection models under investigation. Considering the importance of the negative selection process in the establishment of a competent immune system, it is essential that these discrepancies be fully resolved. In this study, we failed to identify a role for TRAIL in an acute model of peptide antigenspecific negative selection using a TCR transgenic system as well as antibody-mediated TCR/CD3 ligation in vitro and in vivo. Moreover, thymic dendritic cells, the main cellular mediators of negative selection in the thymus, did not constitutively express TRAIL, and TRAIL receptor (DR5) expression was negative or extremely low on thymocytes. Furthermore, in vitro thymocyte deletion was normal in C57BL/6 TRAIL 2/2 gld mice, suggesting that TRAIL and FasL do not function cooperatively to induce negative selection. These results, combined with the fact that aged C57BL/6 TRAIL 2/2 mice showed no signs of spontaneous autoimmunity, strongly indicate that intrathymic negative selection occurs normally in the absence of TRAIL signaling.
Introduction
Bone marrow-derived progenitor T cells undergo a series of maturation events in the thymus to ensure that T cells exported to the periphery are capable of interacting with self-MHC, but do so with a sufficiently low affinity to avoid autoreactivity. CD4 + CD8 + [double positive (DP)] thymocytes that express TCRs with a low affinity for peptide-MHC undergo positive selection (1, 2) and can exit to the periphery where they circulate throughout the secondary lymphoid organs awaiting encounter with antigen (2). In contrast, DP thymocytes that express TCRs that recognize self-peptide-MHC with a high affinity and are potentially self-reactive may undergo negative selection leading to apoptosis (3). Negative selection is important for the generation of a selftolerant peripheral T-cell repertoire and recent studies have reiterated the importance of negative selection in the prevention of autoimmune disease (4-7). Depending on the model system used, negative selection appears to occur at the immature DP stage of thymocyte differentiation in the thymic cortex and possibly later at the single-positive (SP) HSA hi semi-mature stage when thymocytes transit through the cortico-medullary junction (8, 9) .
The molecular mechanisms that underlie the death of autoreactive thymocytes in negative selection are yet to be fully understood, although a number of factors play a role in the process. Intracellular signaling factors that are important for negative selection include the Nur-77/Nurr1/Nor1 transcription factor family (10) (11) (12) and the pro-apoptotic Bcl-2 family members Bim (6), Bax and Bak (13) . More controversial is the contribution made by the death receptors (DRs); members of the tumor necrosis factor (TNF) receptor family containing an intracellular death domain [e.g. Fas, TNF-R1 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors] (14) (15) (16) (17) . Several members of the TNF superfamily have been investigated for their role in negative selection, including TRAIL (CD253), Fas (CD95), TNF, DR3, LT, LIGHT (CD258) and CD30 (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) . These studies tend to suggest that TNF superfamily members do not play a role in negative selection, although there have been some conflicting reports. For example, Kishimoto et al. (23) suggest a role for Fas at high-, but not low-intensity TCR stimulation, whereas other investigators propose that Fas signaling is dispensable for negative selection (30, 31) . Importantly, negative selection occurs normally in Fas associated death domain protein (FADD)-dominant-negative mice (32) and in transgenic mice lacking caspase-8 function (33) , suggesting that DRs (that utilize this pathway to induce apoptosis) may not be essential for negative selection.
Negative selection has been reported to be partially impaired in TRAIL-deficient mice and in the presence of blocking soluble TRAIL receptor (DR5) (24, 28) . These reports clearly contrasted with a previous study that used soluble blocking TRAIL-R2-Fc to demonstrate that negative selection of mouse and human thymocytes appeared to be TRAIL independent (26) , and studies that excluded a role for the FADD-caspase-8 pathway (31) (32) (33) that is necessary for TRAIL signaling. It has been proposed that TRAIL might utilize an alternative apoptosis signaling pathway that does not involve FADD-caspase-8, but may activate Bim and Bax/ Bak (34) . Indeed, Corazza et al. (28) have recently shown that activation-induced Bim expression is decreased in thymocytes lacking TRAIL function. However, our laboratory showed that at least some models of negative selection appear to be normal in TRAIL-deficient mice (27) and another report showed normal negative selection in DR5-deficient mice (16) . One potential problem in these assays of negative selection was the absence of a conventional peptide antigeninduced negative selection model which is arguably the most physiologically relevant system, whereas such a model was included in the Lamhamedi-Cherradi study (24) . Therefore, we have carried out further experiments to specifically examine peptide antigen-induced negative selection, as well as an additional in vivo anti-CD3-induced negative selection model, to determine whether TRAIL might be selectively involved in these models of negative selection. Expression of TRAIL and TRAIL receptor (DR5) on various cell types within the thymus is also examined along with an assessment of spontaneous autoimmune disease in aged TRAIL À/À mice.
Methods

Mice
Inbred BALB/c wild-type (WT), C57BL/6 WT and C57BL/6 OT-I TCR transgenic mice were purchased from The Walter and Eliza Hall Institute of Medical Research (Parkville, Victoria, Australia). BALB/c TRAIL-deficient (BALB/c TRAIL À/À ) and C57BL/6 TRAIL-deficient (C57BL/6 TRAIL À/À ) mice were generated by homologous recombination in 129-derived embryonic stem cells as described (35) and have been backcrossed for 10 generations onto C57BL/6 and BALB/c backgrounds. C57BL/6 gld (FasL mutant) (36, 37) mice were originally obtained from Heinrich Korner, the Centenary Institute of Cancer Medicine and Cell Biology, Sydney, Australia, and bred at the Peter MacCallum Cancer Centre (Peter Mac), East Melbourne, Victoria, Australia. C57BL/6 TRAIL À/À gld mice were established at Peter Mac by crossing C57BL/6 gld and C57BL/6 TRAIL À/À mice (n = 10 backcrossed to C57BL/6) and subsequently interbreeding of the F 1 generation. C57BL/6 DR5-deficient (C57BL/6 DR5 À/À ) mice (16) In other experiments, fetal thymic lobes were isolated from day 15 C57BL/6 OT-I TCR transgenic embryos, cultured for 3 days in supplemented media and then cultured in the presence or absence of OVAp (20 lM) with or without anti-TRAIL mAb (200 lg ml À1 ), for 24 h to allow peptide-induced negative selection to occur. To ensure that the anti-TRAIL mAb was neutralizing from the outset, this reagent was added 30 min prior to the OVAp. At the end of culture, thymocytes were harvested from lobes, counted and analyzed by flow cytometry. Nonviable cells were identified by staining with 7-amino Actinomycin D (7AAD) (Molecular Probes, Carlsbad, CA, USA).
Anti-CD3 ligation in vitro
For in vitro analysis, thymocyte suspensions were produced from thymic lobes isolated from adult C57BL/6 WT, C57BL/6 TRAIL À/À , C57BL/6 gld or C57BL/6 TRAIL À/À gld mice. Cells were cultured at a density of 1 3 10 6 cells ml À1 in DMEM medium (Invitrogen Life Technologies Corp.) supplemented with 10% FCS in wells of a 96-well plate that had been coated overnight or at 37°C for 1 h with hamster anti-mouse CD3e (145-2C11), anti-CD28 (37.51) mAb (both sourced from BD Biosciences PharMingen, San Diego, CA, USA) and/or PBS. Twenty hours later, proportions of live and apoptotic/dead cells were identified by staining with propidium iodide (PI) (Sigma Chemical Co., St Louis, MO, USA) and Annexin V-FITC (Roche, IN, USA). Live cells were considered to be PI À and Annexin V-FITC À .
Anti-CD3 antibody treatment in vitro
Eight-week-old BALB/c and BALB/c TRAIL À/À mice were injected intra-peritoneally (i.p.) with 2, 10 or 20 lg anti-CD3 mAb (145-2C11) or with vehicle control PBS. Forty hours after injection, mice were sacrificed, their thymi and spleens isolated, cells counted and analyzed by flow cytometry. In other experiments, 8-week-old BALB/c and BALB/c TRAIL À/À mice were injected i.p. with 25 lg anti-CD3 mAb at 0 and 24 h. Twenty-four hours after the last injection, mice were sacrificed, their thymi and spleen isolated, cells counted and analyzed by flow cytometry.
Thymic dendritic cell isolation
Thymi were dissected from 8-week-old C57BL/6 WT, C57BL/ 6 TRAIL À/À , BALB/c WT and BALB/c TRAIL À/À mice. Thymocytes were removed by cutting four to six small nicks in each thymic lobe, placing the lobes in RPMI-1640 and agitating with a wide-bore Pasteur pipette. The thymic lobes were then passed through a 100-lm wire mesh to obtain a dendritic cell (DC)-enriched single-cell suspension. DCs were identified by flow cytometry as CD45
Flow cytometric analysis 
Histology
For aging experiments, C57BL/6 and C57BL/6 TRAIL À/À mice were sacrificed between 555 and 700 days and a full autopsy performed. Kidney, spleen and pancreas were examined for signs of autoimmune disease (inflammation and tissue destruction) by histology (hemotoxylin and eosin staining) after fixing these tissues in formalin. The preparation and staining of sections for histology was carried out by Brenda Aisbett (Histology Laboratory, Peter Mac).
ELISA
Sera from aged C57BL/6 WT and C57BL/6 TRAIL À/À mice and from 28-week-old C57BL/6 gld mice were tested by ELISA for total IgG and total anti-double-stranded (ds) DNA antibodies as described previously (39) . The results were expressed in relation to the mean level of serum anti-dsDNA antibodies of 28-week-old C57BL/6 gld mice.
Results
SIINFEKL-induced depletion of OT-I thymocytes developing in fetal thymic organ culture
We first examined acute intrathymic deletion of C57BL/6 OT-I TCR transgenic thymocytes induced by agonist peptide in fetal thymic organ culture by culturing E15 C57BL/6 OT-I thymic lobes for 3 days to allow the development of DP thymocytes, and then treating some of the cultures for 24 h with SIINFEKL peptide (OVAp) with or without neutralizing antimTRAIL mAb (200 lg ml À1 ). OVAp induced almost complete deletion of OT-I DP thymocytes, and the addition of neutralizing anti-mTRAIL mAb afforded no protection against negative selection (Fig. 1A) . Deletion of DP thymocytes in cultures incubated with agonist peptide was also reflected by a decrease in total cell numbers per thymus lobe (Fig. 1B) and an increase in the percentage of non-viable cells as determined by staining with 7AAD (Fig. 1C) . The TRAILspecific antibody was from the same preparation that we have previously shown to block TRAIL-dependent killing in vitro at a 20-fold lower antibody dose (35) .
To investigate whether TRAIL influences negative selection at lower levels of TCR signaling, a longer term culture of E15 C57BL/6 OT-I thymic lobes was performed [as per reference (40)] in the presence of 0-10 À5 M OVAp with or without antimTRAIL mAb (200 lg ml À1 ) for 7 days. OVAp deleted both DP and SP thymocytes in a dose-dependent manner and the presence of anti-mTRAIL mAb had no effect on deletion in this model (Fig. 2) . These results indicate that TRAIL does not play a critical role in thymocyte negative selection induced by agonist peptide in vitro. The residual CD8 SP cells following peptide challenge express low levels of Va2 Tg TCR (mean channel fluorescence ;10 2 compared with ;10 3 for CD8 SP cells without OVAp, data not shown). Although it is possible that some of these cells are immature CD8 SP, based on our analysis of cell numbers, we believe it more likely that the majority of these cells has downregulated their TCR following peptide stimulation.
Anti-CD3 mAb-mediated apoptosis in vitro
One widely used model of negative selection is in vivo administration of anti-CD3 mAb. I.p. injection of 20 lg anti-CD3 mAb into BALB/c WT mice depleted ;70 to 80% of DP thymocytes by 40 h, and equivalent depletion was observed in BALB/c TRAIL À/À mice (Fig. 3A) . Depletion of DP thymocytes in mice injected with anti-CD3 mAb was reflected by a decrease in total numbers of cells per thymus and total numbers of DP cells per thymus (Fig. 3B) . Anti-CD3 mAb treatment also induced depletion of CD4 + HSA hi semi-mature thymocytes that are known targets of negative selection, but not mature CD4 + HSA lo or CD8 + HSA lo thymocytes that have previously been shown to be resistant (Fig. 3C) (9) . To examine any minor differences that might occur when using sub-optimal doses of anti-CD3 mAb, a dose-response study (0, 2 and 10 lg anti-CD3 mAb in vivo) was undertaken (Fig. 3B) . A similar observation has also been made with TRAIL receptor-deficient mice (41) . There was no apparent difference in spleen or LN cellularity between the strains.
Anti-CD3/CD28 mAb-induced apoptosis in vitro
The third model of negative selection tested was in vitro exposure of thymocytes to anti-CD3 and anti-CD28 mAb. Using this approach, we have previously shown that TRAIL does not play a role in in vitro deletion of thymocytes isolated from day 18 embryonic mice (27) . However, using the same approach with thymocytes isolated from adult mice, other researchers have reported defective negative selection in TRAIL-deficient mice (24, 28) . We therefore tested thymocytes isolated from adult C57BL/6 TRAIL À/À (TRAIL deficient), C57BL/6 gld [Fas ligand (CD178) mutant] and C57BL/6 TRAIL À/À gld (TRAIL deficient and FasL mutant) mice to determine whether TRAIL was important in this system and to ascertain whether redundancy operated between the TRAIL-and FasL-signaling pathways. There is some evidence that Fas plays a role in negative selection caused by high-affinity ligands (23) , although the importance of Fas in negative selection is not supported by other studies (30) (31) (32) (33) . Apoptosis of total and DP thymocytes was examined by staining with Annexin V (Fig. 4) . Stimulation by plates coated with 20 lg ml À1 anti-CD3 mAb, with or without 10 lg ml À1 anti-CD28 mAb, induced equivalent death in C57BL/6 WT, C57BL/6 gld, C57BL/6 TRAIL À/À and C57BL/6 TRAIL À/À gld thymocytes. These data suggest that neither TRAIL nor FasL plays a role in thymocyte deletion in this system. Moreover, TRAIL and FasL do not appear to function redundantly to induce negative selection in vitro. To test the possibility that our results differed from previously published reports (24) , because of differences in the dose of anti-CD3 mAb used, we also tested plates coated with 1 lg ml À1 anti-CD3 mAb with or without 2 or 20 lg ml À1 CD28 using adult C57BL/6 WT and C57BL/6 TRAIL À/À thymocytes. Under these conditions, we again observed similar levels of cell death between WT and TRAIL À/À thymocytes, which was only apparent at the highest dose of anti-CD28 (Supplementary Figure 3 , available at International Immunology Online).
Expression of TRAIL and TRAIL receptor (DR5) in the thymus
The most potent inducers of negative selection in the thymus are thought to be thymic DCs (42) . If TRAIL is important in negative selection, it would be expected that first, TRAIL is expressed by cells responsible for inducing deletion (primarily DCs) and second, the thymocyte targets of negative selection should also express TRAIL receptor (DR5). Thymic DCs were isolated and identified by flow cytometry as CD45 + CD11c + MHC-II hi . TRAIL expression was not observed on thymic DCs from C57BL/6 mice ( Fig. 5A) and BALB/c mice (data not shown), or freshly isolated thymocyte populations (data not shown), although it was clearly expressed on liver NK cells used as a positive control (Fig. 5B) . A low level of DR5 staining was observed on thymocytes from C57BL/6 (Fig. 5C ) and BALB/c mice (data not shown), whereas no staining was observed on thymocytes isolated from DR5 À/À mice, used as a negative control (Fig. 5C ). Levels of TRAIL 
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+ DP thymocytes. Data represent mean 6 SEM for independent samples from n = 3 C57BL/6, C57BL/6 TRAIL À/À , C57BL/6 gld and C57BL/6 TRAIL À/À gld mice. and DR5 staining were also examined in thymocytes activated with anti-CD3 and anti-CD28 mAb and shown to be unchanged (Fig. 6) . Therefore, while DR5 is present at low levels in the thymus, our inability to detect TRAIL on thymic DCs supports the possibility that TRAIL is not necessary for intrathymic negative selection.
Aged C57BL/6 TRAIL-deficient mice do not develop spontaneous autoimmune disease Inherent defects in intrathymic negative selection are often associated with the development of spontaneous autoimmune disease (4-7). If TRAIL-deficient mice have defective negative selection, they might be expected to exhibit signs of autoimmune disease. Therefore, we assessed C57BL/6 WT and C57BL/6 TRAIL À/À mice >18 months for signs of spontaneous autoimmune disease. Serum isolated from aged mice was analyzed for levels of total IgG (Fig. 7A ) and anti-dsDNA autoantibodies (Fig. 7B) . Serum isolated from 28-week-old C57BL/6 gld mice was used as a positive control, as these mice exhibit elevated levels of serum IgG autoantibodies (43) . Neither total IgG nor anti-dsDNA autoantibodies was elevated in aged C57BL/6 WT or C57BL/6 TRAIL À/À mice ( Fig. 7A and B) , and the mice all appeared healthy. Moreover, the overall lymphocyte composition was comparable in LN, spleen and thymus of aged C57BL/6 WT and C57BL/6 TRAIL À/À mice (Fig. 7C ) and histological analysis of a number of organs, such as the spleen, kidney and pancreas, failed to reveal any obvious signs (such as lymphocytic infiltration or tissue destruction) of spontaneous autoimmune disease in these mice (Supplementary Figure  4 , available at International Immunology Online). Collectively, these findings strongly suggest that the absence of TRAIL does not predispose an individual to spontaneous autoimmune disease.
Discussion
The role of TRAIL signaling in intrathymic negative selection is controversial, with two recent reports (24, 28) suggesting that TRAIL is critical for negative selection of autoreactive thymocytes and other reports suggesting that TRAIL is not required for this process (16, 26, 27, 32, 33) . Although previous studies have shown that TRAIL is dispensible for superantigen and anti-CD3-induced models of negative selection, they did not examine a peptide antigen-specific model of negative selection or did they examine whether there was a level of redundancy with Fas, another DR that has been implicated in negative selection. These issues have been addressed in the current study, which strongly supports the view that TRAIL is not required for negative selection.
TRAIL and DR5 mRNA have previously been detected in whole-mouse thymus (44), DN and DP thymocytes (45) and thymic stromal cells (45) . We also detected low levels of surface DR5 expression on freshly isolated and in vitrostimulated thymocytes, consistent with western blot analysis of whole thymus (41) . The presence of TRAIL and DR5 mRNA in these cell subsets suggests that it might be possible for TRAIL and DR5 protein to be induced under physiological conditions such as the encounter of self-antigen that are not mirrored by in vitro culture and CD3/CD28 mAb stimulation. In support of this notion, a recent study found that TRAIL mRNA is up-regulated in thymocytes following injection with an adenosine receptor agonist; however, the resultant thymocyte apoptosis appeared to occur independently of DRs (46) . The low levels of thymocyte DR5 expression may also form the basis for the subtle resistance of TRAIL-and DR5-deficient thymocytes to radiation-induced cell death (28, 41) . However, a relevant finding in this study was that mouse thymic DCs do not appear to constitutively express TRAIL, and since thymic DCs are important cellular mediators of negative selection in the thymus (42) , their lack of TRAIL expression is consistent with negative selection being TRAIL independent. There is also evidence that thymic epithelial cells may contribute to negative selection (42, 47) ; however, analysis of TRAIL expression on thymic stromal cells by flow cytometry was precluded by an apparent sensitivity of TRAIL to collagenase digestion which we found was essential for generating thymic epithelial cell suspensions (data not shown).
As negative selection is responsible for the removal of potentially autoreactive thymocytes, defects in negative selection are associated with the release of self-reactive T cells into the peripheral pool, which may predispose an individual to autoimmune disease. For example, deficiency of the proapoptotic Bcl-2 family member Bim, that is critical for negative selection, leads to spontaneous development of autoimmune glomerulonephritis (5) . Mutation of autoimmune regulator inhibits the expression of some peripheral antigens in the thymus, preventing the deletion of self-reactive T cells, and predisposes mice (4, 7) and humans (48) to a range of organ-specific autoimmune diseases. In this study, C57BL/6 TRAIL À/À mice showed no evidence of spontaneous autoimmunity, even when aged >18 months. This is consistent with the argument that TRAIL is not critical for maintaining selftolerance through negative selection. However, given the typical dampening of many autoimmune phenotypes on a C57BL/6 background (49-51), it might be of interest to examine whether TRAIL À/À mice develop spontaneous autoimmune disease on a more autoimmune-prone background.
Despite the lack of evidence for spontaneous autoimmune disease in TRAIL À/À mice, we have recently used TRAILdeficient mice, neutralizing anti-TRAIL mAb and recombinant soluble TRAIL/Apo2L to identify a role for TRAIL in suppression of relapsing-remitting and chronic experimental autoimmune encephalomyelitis (52) . Other studies have also demonstrated that TRAIL-deficient mice are more susceptible to the induction of autoimmunity in certain experimental models (24, (53) (54) (55) ; however, it remains unclear by what mechanism TRAIL suppresses the induction of autoimmunity. Disease induction in experimental models of autoimmunity is extremely complex and often involves adjuvants that stimulate DCs and other innate immune cells and activationinduced T-cell death in the periphery. Indeed, several studies have implicated TRAIL in AICD (56) (57) (58) , although it remains to be determined whether TRAIL contributes to the maintenance of self-tolerance in this manner. Given that TRAIL expression can be induced on activated NK cells (38) and DCs (59), the involvement of TRAIL in experimental models of autoimmune disease might be attributed to the effects of adjuvant administered to induce disease. Indeed, CFA administration is known to stimulate NK cell IFN-c production (60, 61) and to suppress autoimmune diabetes (60) and pristane-induced arthritis in mice (62, 63) . Moreover, autocrine IFN-c produced by NK cells has been implicated in the regulation of TRAIL expression (64) . Collectively, these findings entertain the possibility that TRAIL-mediated suppression of experimental autoimmune disease might be acting at the level of peripheral tolerance.
In this study, we were unable to identify a role for TRAIL in thymocyte depletion mediated by CD3 ligation in vivo. Although in vivo exposure of thymocytes to anti-CD3 mAb is a frequently used model to examine negative selection, apoptosis induced in this manner is largely mediated by inflammatory cytokines and steroid hormones produced by peripheral T cells (65, 66) . Therefore, previous reports indicating a role for TRAIL in this model (24, 28) are not necessarily reflective of a role for TRAIL in negative selection, but instead might reflect a role for TRAIL in non-specific forms of thymocyte depletion. Indeed, it remains to be determined whether TRAIL or TRAIL receptor expression is regulated by glucocorticoids or TNF. The results in this study strongly support the contention that TRAIL is not critical for intrathymic negative selection, but suggest that it may have some other, as yet undefined role in regulating thymocyte numbers. We additionally showed that thymocyte deletion is normal in mice deficient in both TRAIL and FasL, suggesting that TRAIL and FasL do not function redundantly to induce negative selection. It might now be of interest to delete multiple TNF superfamily members, to determine whether negative selection is completely independent of DRs, although results from FADDdominant-negative mice and crmA-transgenic mice would suggest that DRs are typically not necessary for negative selection.
Supplementary data
Supplementary Figures 1-4 are available at International Immunology Online. Fig. 7 . Serum antibody concentration and lymphoid organ composition in aged C57BL/6 and C57BL/6 TRAIL-deficient mice. Serum was isolated from aged (>555 days) C57BL/6 and C57BL/6 TRAIL À/À or 28-week-old C57BL/6 gld mice (as a positive control) and tested by ELISA for (A) total concentration of IgG and (B) anti-dsDNA autoantibodies. The concentration of anti-dsDNA autoantibodies is shown relative to that observed for 28-week-old C57BL/6 gld mice (100 U was defined as the mean 6 SEM of absorbance at 405 nm for 28-week-old C57BL/6 gld mice). Mean 6 SEM was calculated from the sera of three C57BL/6, three C57BL/6 TRAIL À/À and four C57BL/6 gld mice. (C) The lymphocyte composition observed in the axillary LN, spleen and thymus of aged C57BL/6 and C57BL/6 TRAIL À/À mice is also shown. Mean 6 SEM was calculated from analysis of cells isolated from three C57BL/6 and five C57BL/6 TRAIL À/À mice.
